These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2681929)

  • 1. Short and long term effects of antihypertensive therapy in the diabetic rat.
    Anderson S; Rennke HG; Garcia DL; Brenner BM
    Kidney Int; 1989 Oct; 36(4):526-36. PubMed ID: 2681929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat.
    Gin T; Joon TL; Panagiotopoulos S; Cooper M; Taylor H; Jerums G
    Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):281-9. PubMed ID: 8603832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
    Anderson S; Rennke HG; Brenner BM
    J Clin Invest; 1986 Jun; 77(6):1993-2000. PubMed ID: 3011863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nifedipine versus fosinopril in uninephrectomized diabetic rats.
    Anderson S; Rennke HG; Brenner BM
    Kidney Int; 1992 Apr; 41(4):891-7. PubMed ID: 1387433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal vascular effects of antihypertensive therapy in uninephrectomized SHR.
    Dworkin LD; Grosser M; Feiner HD; Ullian M; Parker M
    Kidney Int; 1989 Mar; 35(3):790-8. PubMed ID: 2540376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
    Fabris B; Candido R; Armini L; Fischetti F; Calci M; Bardelli M; Fazio M; Campanacci L; Carretta R
    J Hypertens; 1999 Dec; 17(12 Pt 2):1925-31. PubMed ID: 10703891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive therapy must control glomerular hypertension to limit glomerular injury.
    Anderson S; Rennke HG; Brenner BM
    J Hypertens Suppl; 1986 Dec; 4(5):S242-4. PubMed ID: 3553475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy.
    O'Brien RC; Cooper ME; Jerums G; Doyle AE
    Diabetes; 1993 Apr; 42(4):604-9. PubMed ID: 8454112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.
    Cooper ME; Rumble JR; Allen TJ; O'Brien RC; Jerums G; Doyle AE
    Kidney Int; 1992 Apr; 41(4):898-903. PubMed ID: 1513111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes.
    Tang Z; Shou I; Wang LN; Fukui M; Tomino Y
    Nephron; 1997; 76(3):323-30. PubMed ID: 9226234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
    Raij L; Chiou XC; Owens R; Wrigley B
    Am J Med; 1985 Sep; 79(3C):37-41. PubMed ID: 2996345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat.
    Velasquez MT; Striffler JS; Abraham AA; Michaelis OE; Scalbert E; Thibault N
    Hypertension; 1997 Nov; 30(5):1232-7. PubMed ID: 9369281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
    Lehfeld LS; Silveira LA; Ghini B; Lopes de Faria JB
    Kidney Blood Press Res; 2004; 27(2):114-20. PubMed ID: 15051931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glomerular abnormalities in long-term experimental diabetes. Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy.
    Fujihara CK; Padilha RM; Zatz R
    Diabetes; 1992 Mar; 41(3):286-93. PubMed ID: 1551488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxic serum nephritis with hypertension: amelioration by antihypertensive therapy.
    Neugarten J; Kaminetsky B; Feiner H; Schacht RG; Liu DT; Baldwin DS
    Kidney Int; 1985 Aug; 28(2):135-9. PubMed ID: 3834224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
    Zatz R; Dunn BR; Meyer TW; Anderson S; Rennke HG; Brenner BM
    J Clin Invest; 1986 Jun; 77(6):1925-30. PubMed ID: 3011862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implications of converting-enzyme inhibitors in renal disease.
    Anderson S; Brenner BM
    Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):81-7. PubMed ID: 3037894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
    Cooper ME; Allen TJ; O'Brien RC; Papazoglou D; Clarke BE; Jerums G; Doyle AE
    Diabetes; 1990 Dec; 39(12):1575-9. PubMed ID: 2245881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tight blood pressure control on glomerular hypertrophy in a model of genetic hypertension and experimental diabetes mellitus.
    Amazonas RB; Lopes de Faria JB
    Life Sci; 2006 Oct; 79(22):2135-43. PubMed ID: 16890245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.